Compound Screening TRIZ Cases

A magnetic levitation system balances forces to separate and monitor heterogeneous cell populations in real time.

Single cell profiling of circulating tumor cells identifies biomarkers linked to abiraterone and enzalutamide response.

Targeting soluble E-cadherin EC2-EC5 subdomains with antibodies selectively kills cancer cells, avoiding systemic toxicity from non-selective chemotherapeutics.

Anti-CD36 antibodies and shRNA block fatty acid transport to impair metastatic initiation and reduce lymph node tumor size.

Synaptogyrin-3 inhibitors block Tau association with synaptic vesicles, rescuing presynaptic function in tauopathies.

A 3D collagen hydrogel system enables real-time imaging of matrix vesicle calcification.

Segmenting myeloid subsets with LILRB blocking antibodies overcomes PD-1 therapy limitations by reprogramming immunosuppressive cells.

A kidney-on-a-chip device uses a horizontal multi-compartment structure to co-culture renal tubular epithelial cells and fibroblasts.

Engineered monoclonal antibody-drug conjugates bind Axl receptors and trigger cellular internalization to deliver cytotoxic payloads.

A multiplexed mass spectrometry method evaluates binding affinity across multiple receptor targets simultaneously.

Cell-based assay replaces fluorescent methods to improve measurement accuracy and throughput for ion channel screening.

Cationic ion pairing chromatography coupled with mass spectrometry detects and quantifies cytidine triphosphate levels in cell samples.

Droplet bilayer formation measures ion channel activity via optical detection of volume changes, eliminating cell toxicity and fluorescence noise.

Macrocyclic peptides block PD-L1 interactions, restoring T cell activity for cancer treatment.

Analyzing gene expression changes during contact normalization allows accurate diagnosis of metastatic potential while sparing noncancerous cells.

Segmented monoclonal antibodies quantify sAPPβ fragments to resolve measurement precision limits in BACE1 activity assessment.

Porous Transwell membranes mimic the lamina propria to sustain intestinal stem cell proliferation and self-renewal in long-lived monolayers.

A dynamic microfluidic ex vivo system sustains multiple myeloma cells through continuous nutrient perfusion and 3D bone marrow niche recreation.

Rational scanning mutagenesis enhances mutant TSHR thermostability for stable autoantibody detection.

A type IV collagen-like immunoreactive peptide binds specific chronic nephritis autoantibodies in biological samples.

Human iPSC-derived neuronal models identify therapeutic compounds that rescue cellular defects in CDKL5 deficiency.

Soluble CD33 antagonists sequester S100A9 to block MDSC activation, restoring hematopoiesis and improving therapeutic durability in myelodysplastic syndromes.

Specialized antibodies bind phosphorylated PD-1 to resolve detection precision limits in assessing T cell function during immunotherapy.

Purified serum factors reduce inflammatory responses in animal models, resolving the contradiction between model reliability and species resistance.

Papio cynocephalus TLR3 polynucleotides express proteins to resolve species cross-reactivity challenges in therapeutic development.

A competitive binding assay using fluorescent probes calculates compound affinity and dissociation rates against target proteins.

AAV9 vectors deliver BAG3 genes to restore ventricular function, addressing inadequate genetic treatment for dilated cardiomyopathy.

Phosphorylated ubiquitin protein at serine 65 serves as a specific biomarker for detecting Parkinson's disease.

Allosteric monobody targets Aurora A kinase PIF pocket, disrupting TPX2 binding to resolve ATP-site specificity conflicts.

Inserting SCN5A into host cells creates a stable Nav1.5 model that resolves signal-to-noise ratio issues in drug safety testing.

Engineered aglycosylated Fc domains with specific amino acid substitutions enable selective binding to activating Fc receptors.

Selective prebiotic compositions enrich short-chain fatty acid-producing bacteria while suppressing endotoxin-producing bacteria to improve insulin sensitivity.

CUDC-907 targets pituitary corticotroph tumors to reduce ACTH secretion, addressing low compliance and side effects of adrenal-directed inhibitors.

A nucleic acid-display library screens binding polypeptides against intact cell surfaces to isolate high-affinity binders.

Blood-brain barrier permeable histone acetyltransferase activators resolve compound impermeability to reduce amyloid-beta deposits.

TLR2 antagonists reduce glomerular inflammation without systemic immune suppression.

Gut-homing lymphocyte levels predict treatment response to beta7 integrin antagonists.

Cysteine substitution creates disulfide bonds to stabilize integrins in a closed conformation.

Stabilized prefusion spike proteins coupled to solid supports quantify neutralizing antibodies without live virus handling or biosafety level facilities.

Introducing hTERT and SV40 large T-antigen genes enables the cell line to induce liver fibrosis without inhibiting hepatic cell function.

Labeled sulfinic acid probes form stable adducts with nitrosothiols to resolve selectivity issues in complex proteomes.

Targeting T cell adhesion molecule TARM with specific antibodies blocks immune activation and prevents bone destruction in rheumatoid arthritis.

Segmented in vitro systems using labeled tRNAs resolve direct versus indirect drug mechanisms to enable precise therapeutic compound identification.

A method ranks tumor-specific neo-epitopes using the Differential Agretopic Index and conformational stability metrics.

Targeting LANCL2 proteins enables selective PPARγ activation to manage blood glucose and inflammation while avoiding liver damage and weight gain.

A TR-FRET biosensor detects structural changes in the myosin and MyBP-C complex using fluorescent probes.

Solid polymer film partitions enable liquid flow detection of enzyme activity, resolving solubility and reproducibility bottlenecks in screening.